

GenesisCare Annual Research Report 2024





Contents

Introduction	04
Key stakeholders	08
Research in numbers	16
Research locations	18
Medical oncology	20
Radiation oncology	21
Theranostics	22
Haematology	23
MR-Linac program	24
Investing in the future of cancer care	26
Quality	28
Partnerships	29
Sponsorships and events	30
Partnering with consumers	32
A patient's journey with clinical trials	34
Publications for 2024	36

Introduction

From Dr Marie Burke OAM

Chief Medical Officer, GenesisCare Australia

Every new therapeutic discovery and development is born from clinical research. Many treatments that are now considered standard of care and administered globally started off at a laboratory bench somewhere, with a dedicated and curious group of doctors and researchers. Clinical research is a critical component in expanding treatment options, and our involvement allows us to collect high-quality clinical evidence to inform treatment protocols and deliver better outcomes for our patients.

Everything we have achieved this year would not have been possible without our dedicated doctor group and research team who challenge themselves every day to find new and better ways to treat illness and disease. In 2024, the GenesisCare Research team published 63 articles of which 33 were peer reviewed articles. I'm proud to share we have >150 active research projects across 45 sites, with >3000 patients taking part in a clinical trial or registry. Thank you to our wonderful team for this amazing achievement.

It's also important to note that our research program would not be possible without the ongoing support and collaboration of all our research partners, old and new, who partner with us on significant research projects.

Finally, every progress we have made, and new therapies approved by regulators, would not be possible without the voluntary participation of patients, who have the courage and bravery to participate in clinical research. Without our patients, we would not be able to uncover new treatments and help advance cancer care.

GenesisCare is committed to service line expansion and investment in research and clinical trials. I'm excited to see what 2025 has in store, as we continue our mission to find new and better ways to deliver the best possible life outcomes for our patients.

Best wishes,



Dr Marie Burke OAM

MBBS, FRANZCR

Chief Medical Officer, GenesisCare Australia
Radiation Oncologist

Introduction

From Sonya McColl
Head of Research, GenesisCare Australia

Welcome to GenesisCare's Annual Research Report.

As Head of Research at GenesisCare, I couldn't be more proud of the remarkable progress our doctors and research teams have made this year. The dedication and innovation demonstrated across our research network is a testament to the passion and expertise of our doctors, clinical teams, research teams, and support staff. I am truly grateful for the opportunity to work alongside such talented individuals, whose commitment to advancing cancer care continues to inspire me every day.

Over the past year, we've witnessed several exciting and impactful trends in cancer research. Four key areas stand out:

1 Personalised Medicine and Biomarkers

The growing emphasis on personalised treatment plans, driven by genetic insights, is transforming cancer care. Research into biomarkers is unlocking new possibilities for precision therapies, offering patients more effective and targeted treatment options.

2 Theranostics & Radiopharmaceuticals

The integration of diagnostics and therapy through radiopharmaceuticals, along with the use of new isotopes, is reshaping how we deliver radiation therapy. This approach allows for more accurate targeting of cancers, reducing side effects and providing new hope for patients.

3 Growth in Early-Phase Trials

We've seen a significant increase in early-phase trials for solid tumours, haematology, and theranostics here in Australia. This highlights our country's growing role in global cancer research, giving patients faster access to advanced therapies.

4 Combination Therapies

Based on molecular and preclinical cancer research, combination therapies are becoming increasingly prominent. More and more, cancer treatments are taking the form of combinations of drugs or integrating different modalities—such as radiopharmaceuticals with radiation sensitisers, immunotherapies, or external beam radiation therapy.

This year has been marked by significant milestones achieved by our team, and I'm thrilled to share a few of the highlights:

- Both our MR-Linac and North Shore Research teams were nominated for awards in the prestigious's 2024 NSW Premier's Awards for Outstanding Cancer Research. The MR-Linac Team was nominated for the **Cancer Control Innovation Award**, and the North Shore Research Team was a finalist for the **Outstanding Cancer Clinical Trials Unit Award**.

- We have now partnered with **over 20 radiopharmaceutical companies** to conduct early-phase theranostics clinical trials, with the aim of delivering improved outcomes for our current and future patients

- The MR-Linac Team became the first globally to deliver **Prostate SABR treatment via a 'sim-less' workflow**, and their pioneering work in integrating MRI with radiation therapy has been featured in numerous publications.

- Wide Bay in Queensland also received **significant media attention**, showcasing the impactful research and clinical work taking place in regional areas— which continues to be an important priority for GenesisCare.

These achievements reflect the extraordinary work happening across GenesisCare. We are excited to continue building on this momentum, and I'm deeply grateful to everyone involved for their tireless efforts to help improve the lives of cancer patients worldwide.

Thank you for your continued support. I hope you find this report insightful and inspiring. Together, we are making a profound difference in the fight against cancer.



Sonya McColl

Head of Research,
GenesisCare Australia

Key stakeholders

2024 principal investigators

Radiation oncology



Dr Marie Burke OAM

Clinical interests in breast, gynaecological, and skin cancers.



A/Prof Peter O'Brien

Clinical interest in breast and gynaecological, sarcoma, palliative and lymphoma.



Prof Jarad Martin

Clinical interest in prostate, bladder, rectal, anal, gastrointestinal cancers, and benign conditions (including Dupuytren's disease and Ledderhose disease).



Dr Marcus Dreosti

Clinical interests include breast, prostate, gastrointestinal and gynaecological.



A/Prof Michael Ng

Clinical interests in prostate, breast, lung, and gastrointestinal cancers, lymphoma and stereotactic radiation therapy.



Dr Yvonne Zissiadis

Clinical interests in breast cancer, gastrointestinal cancers, and haematology.



Dr Jeremy de Leon

Clinical interests in upper gastrointestinal, urogenital, lung cancers and advanced treatment technology including MR-Linac.



A/Prof Peter Graham

Clinical interests in breast cancer, lung cancer, head and neck cancer, plus skin cancer.



Prof June Corry

Clinical interests in head and neck and skin cancers.



Prof Michael Chao

Clinical interests in breast, lung, and prostate cancers.



Dr Bradley Wong

Clinical interests in skin cancer, prostate cancer, urological cancers, breast cancer, palliative care, and benign conditions.



Dr David Schlect

Clinical interests in neurological, brain and spine, lung, and skin cancers, sarcoma, benign conditions (including Dupuytren's disease, keloid scars), and rare tumours.



Dr Gerry Adams

Clinical interests in head and neck cancers, skin malignancies, central nervous system (CNS) and general oncology.



Prof David Christie

Clinical interests in urological (including prostate) cancers, and skin cancers plus benign conditions.



Dr Joseph Bucci

Clinical interests in urogenital, gastrointestinal, lymphoma, and palliative care.



Prof Bryan Burmeister

Clinical interests in gastrointestinal, skin, lung, head and neck, sarcoma, and oesophageal malignancies, general oncology, and clinical research.

Key stakeholders

2024 principal investigators

Radiation oncology



Dr James MacKean

Clinical interests in breast cancer, melanoma, liver malignancies, and upper gastrointestinal malignancies.



Dr Sandy Sampaio

Clinical interests in brain & spine cancer, gastrointestinal cancer and palliative cancer.



Dr Mario Guerrieri

Clinical interests in urological, breast, lung, prostate and gastrointestinal malignancies.



A/Prof Karen Taylor

Clinical interest in breast cancer, palliative care and stereotactic radiation therapy.



A/Prof Tee Lim

Clinical interests in breast, urological, gastrointestinal, and lung cancers.



Dr Anne Capp

Clinical interests in genitourinary, colorectal and gynaecological cancers, haematological malignancies and palliative care.



Dr Phuong Tran

Clinical interests in breast cancer, urological including prostate cancer, lung malignancies, and palliative care.



Dr Andrew Potter

Clinical interests in breast, lung, skin, urological, gynaecological, haematological, prostate, and central nervous system cancers, plus palliative care.



Dr Sagar Ramani

Clinical interests in genitourinary, lung, breast, colorectal and gastrointestinal cancers.



Dr Eric Wegener

Clinical interests in prostate cancer, skin cancer, brain and spine cancers, gastrointestinal cancer, genitourinary cancer, and lung cancer.



A/Prof Sid Baxi

Clinical interests in skin, head and neck, thoracic, blood, liver, brain, breast, and gastrointestinal cancers.



Dr George Papadatos

Clinical interest in breast, skin, central nervous system (CNS), and haematological malignancies, plus general palliative care.



A/Prof Gillian Lamoury

Clinical interests in breast cancer, sarcoma, palliative oncology, and benign diseases.



A/Prof Tim Wang

Clinical interests in breast cancer, melanoma, liver malignancies, and upper gastrointestinal malignancies.



Dr Gina Hesselberg

Clinical interests in breast cancer, upper gastrointestinal cancer, liver cancer, neuroendocrine tumours, and palliative care.



Dr Farshad Kasraei

Clinical interests in brain, spine and upper gastrointestinal tumours, plus skin cancer, genitourinary cancer and benign conditions.



Dr Katherine Neville

Clinical interests in breast, skin, and lung cancers, palliative care radiation therapy, and haematology



Prof Mike Fay

Clinical interests in theranostics, plus gastrointestinal, skin, and lung cancers, neuro-oncology, and palliative care

Key stakeholders

2024 principal investigators

Radiation oncology



Dr Matt Mason

Clinical interests in head and neck cancer, breast cancer, skin cancer, prostate cancer, and palliative care.



Dr Kasri Rahim

Clinical interest in non-melanomatous skin cancer.



Dr Art Kaminski

Clinical interests in lung, liver, bone, brain, spine, and skin cancers.



Dr Hendrick Tan

Clinical interests in neuro-oncology (brain, skull base, spine), SABR/SRS, MRIgRT adaptive RT, thoracic, oligometastases, upper gastrointestinal, skin and urological cancers.



Dr Mark Sidhom

Clinical interest in genitourinary cancers (including prostate, bladder and kidney cancer).



Dr Esther Sim

Clinical interests in breast, lung, neurological, skin cancers and general oncology.



Dr Joshua Sappiatzer

Clinical interests in breast cancer, lung cancer, urological cancers, gastrointestinal cancers, central nervous system tumours, head and neck cancers, and skin malignancies, plus benign conditions such as Dupuytren's contracture.



Prof Angela Hong

Clinical interests in melanoma, skin, sarcoma, lymphoma and neurological cancers.

Medical oncology



A/Prof Connie Diakos

Clinical interests in breast, gastrointestinal, neuroendocrine tumours, and gynaecological cancers.



Prof Nick Pavlakis

Clinical interest in lung and gastrointestinal cancers, mesothelioma and neuroendocrine tumours.



Dr Sally Barron Hay

Clinical interests in breast cancer and gynaecological malignancies.



Prof Stephen Clarke

Clinical interests in thoracic and gastrointestinal cancers including neuroendocrine tumours and mesothelioma.



A/Prof Nick Murray

Clinical interests in breast and gynaecological cancers.



Dr Ayesha Salim

Clinical interests in melanoma, autologous T-cells and theranostics clinical trials.



Dr Mark Macgregor

Clinical interests in gastrointestinal, genitourinary, breast and lung cancers.



Dr Vy Broadbridge

Clinical interests in lung, gynaecological, melanoma, gastrointestinal and breast cancers.

Key stakeholders

2024 principal investigators

Medical oncology



Dr Adrian Lee

Clinical interest in genitourinary, brain, plus head and neck cancers.



Dr David Chan

Clinical interest in gastrointestinal, genitourinary and neuroendocrine cancers.



Dr Sarah Maloney

Clinical interests in gastrointestinal and respiratory cancers.



Dr Laurence Krieger

Clinical interests in prostate, bladder, kidney, and testicular cancers.

Haematology



Dr David Kliman

Clinical interest in lymphoma, myeloma, leukaemia, cellular therapies, thrombosis and general haematology.



Dr. Wilfred Jaksic

Clinical interests in lymphoma and general haematology.



Dr. Anya Hotinski

Clinical interest in general haematology.



A/Prof Ian Lewis

Clinical interests include lymphoma, myelodysplastic and myeloproliferative disorders as well as general haematology.

Theranostics



A/Prof Joe Cardaci

Clinical interests in prostate cancer and neuroendocrine tumours.



Dr Aviral Singh

Clinical interests in Theranostics.



A/Prof Dinesh Sivaratnam


Clinical interests in metastatic prostate cancer.



Dr Nick Myles

Clinical interests in general haematology, benign haematological conditions including bleeding disorders and management of venous thromboembolism.

Research in numbers – 2024



150 Active research projects

109 Interventional
21 Prospective observational
28 Retrospective observational



112

External sponsors



3689 Total patients participating in research

2225 Patients in observational studies
1464 Patients in interventional studies



152

Number of active Research investigators

Top disease sites



31

Prostate



24

Breast



17

Lung



63

Published articles



45

Number of research sites



54

Dedicated research FTE



7

Grant applications



28

External research projects where GC is contributing real world data



Research Locations

WA

1.	Bunbury (RO, Ph II – Ph IV, O)
2.	Fiona Stanley Hospital (RO, Ph II – Ph IV, O)
3.	Wembley (RO, Ph II – Ph IV, O)
4.	Shenton House – Joondalup (RO, Ph II – Ph IV, O)
5.	Mandurah (RO, MO, Ph II – Ph IV, O)
6.	Hollywood (RO, THA, Ph II – Ph IV, O)
7.	Murdoch (RO, THA, Ph I – Ph IV, O)
8.	Albany (RO, O)

SA

9.	Kurralt Park (RO, Ph II – Ph IV, O)
10.	St Andrew's Precinct (RO, THA, HAEM, MO, Ph I – Ph IV, O)
11.	Bedford Park – Flinders Private Hospital (RO, Ph II – Ph IV, O)
12.	North Adelaide (MO, HAEM, Ph I – Ph IV, O)
13.	Elizabeth Vale (Playford Health Hub) (MO, RO, Ph II – Ph IV, O)

QLD


14.	Rockhampton (RO, O)
15.	Bundaberg (RO, MO, Ph II – Ph IV, O)
16.	Fraser Coast (St Stephen's Hospital) (RO, MO, Ph II – Ph IV, O)
17.	Noosa (RO, O)
18.	Buderim (RO, O)
19.	Chermside (RO, Ph II – Ph IV, O)
20.	Wesley Medical Centre (RO, Ph II – Ph IV, O)
21.	Southport (RO, Ph II – Ph IV, O)
22.	Tugun (RO, THA, Ph II – Ph IV, O)

NSW

23.	Newcastle (RO, Ph II – Ph IV, O)
24.	Mater Hospital (RO, Ph II – Ph IV, O)
25.	Darlinghurst (St Vincent's Hospital Campus) (RO, Ph II – Ph IV, O)
26.	Hurstville (RO, MO, HAEM, Ph II – Ph IV, O)
27.	Frenchs Forest (RO, MO, HAEM, Ph II – Ph IV, O)
28.	North Shore Health Hub (RO, MO, THA, HAEM, Ph I – Ph IV, O)
29.	Kingswood (RO, MO, Ph I – Ph IV, O)
30.	Maitland (RO, MO, THA, Ph II – Ph IV, O)
31.	Norwest (RO, O)
32.	Campbelltown (RO, MO, HAEM, Ph I – Ph IV, O)
33.	Macquarie University (RO, Ph II – Ph IV, O)

VIC

34.	Epping (RO, Ph II – Ph IV, O)
35.	Footscray (RO, Ph II – Ph IV, O)
36.	Frankston (RO, Ph II – Ph IV, O)
37.	St Vincent's, Melbourne (RO, Ph II – Ph IV, O)
38.	Cabrini (RO, MO, THA, Ph I – Ph IV, O)
39.	Berwick (RO, Ph II – Ph IV, O)
40.	Ringwood (RO, Ph II – Ph IV, O)
41.	Albury Wodonga (RO, Ph II – Ph IV, O)
42.	Shepparton (RO, Ph II – Ph IV, O)
43.	Peninsula Private Hospital (RO, Ph II – Ph IV, O)



National quick look

- RO** All sites except North Adelaide
- MO** North Shore, Frenchs Forest, Kingswood, Hurstville, Maitland, Campbelltown, Bundaberg, Hervey Bay, St Andrews Precinct, North Adelaide, Playford, Cabrini, Mandurah, Bunbury, Wembley
- THA** North Shore, Maitland, Tugun, St Andrew's Precinct, Cabrini, Murdoch, Hollywood
- HAEM** North Shore, Frenchs Forest, Hurstville, St Andrew's Precinct, North Adelaide, Campbelltown

Legend

- RO = Radiation Oncology
- MO = Medical Oncology
- THA = Theranostics
- HAEM = Haematology
- Phase I = Ph I
- Phase II = Ph II
- Phase III = Ph III
- Phase IV = Ph IV
- O = Observational

Medical oncology



Combination With other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion. AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor representing novel method in anti-cancer treatment of MTAP-deleted cancers. This approach showed promising results in first in human trials.²

Study Investigator, Prof Nick Pavlakis has this to say about the future of pancreatic cancer clinical research:



With modest benefits from chemotherapy and low overall survival rate, pancreatic cancer remains one of the most important areas of unmet clinical need in oncology.

As seen in other cancers, with greater investment in research, clinically meaningful discoveries will come. Fortunately, with great efforts, new promising therapies in pancreatic cancer are being discovered with the help of high-quality research to improve outcomes for our patients. I believe it will be only a matter of time to see the next breakthroughs in this disease.

With over 38 active Medical Oncology trials, 29 in follow up and 9 in startup – it is evident our GenesisCare Research and Leadership teams are dedicated to providing quality clinical research to the Australian community. At present the Australian five-year survival rate for pancreatic cancer is 13% and 3 out of 10 people (37%) will survive one year after diagnosis of pancreatic cancer.¹

Principal Investigator, Medical Oncologist, Prof Nick Pavlakis is helping lead the way to assist with clinical research in this field. He is currently investigating subjects with Advanced Pancreatic Ductal Adenocarcinoma which has one of the poorest survival rates across all solid tumours, and a very high unmet need.

The AMG193 20230223 trial is a Phase 1b study evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in



68

Clinical trials



13

Observational studies



9

Publications



40

Investigators



684

Patients in research



66

External sponsors



14

Research sites

Breast, Lung, Prostate

Top disease sites

Radiation oncology



their test results. As many patients remain wary of hormone therapy due to its potential side effects, the ASTuTE trial offers a valuable opportunity for informed decision-making and the potential to avoid unnecessary treatments.

Radiation Oncologist, Dr Eric Wegener one of the ASTuTE study Principal Investigators and various Radiation Oncology research studies with GenesisCare had this to say about the study and its potential for transforming prostate cancer treatments,



AI-powered biomarker reshapes prostate cancer treatment decisions, reducing overtreatment and giving ASTuTE prognostic information to help shared ADT decisions.

Our GenesisCare clinical research team currently have 23 active radiation oncology trials with 27 in follow up and 7 in their start up phases. One of our Radiation Oncology studies, ASTuTE, is a study researching the use of artificial intelligence to help clinicians and patients make informed decisions about Androgen Deprivation Therapy (ADT), commonly known as hormone therapy, in combination with radiotherapy, in the management of prostate cancer.

As of December 2024, the ASTuTE study has successfully enrolled 296 nationally. A review of 208 patients has been conducted of which 77 patients who initially agreed to ADT, 67% changed their decision to no after receiving



18

Clinical trials



35

Observational studies



47

Publications



96

Investigators



2941

Patients in research



38

External sponsors



42

Research sites

Breast, Benign, Prostate

Top disease sites

Theranostics



small cell lung cancer (ES-NSCLC). The ⁶⁸Ga-SS120 imaging compound is used to identify the target somatostatin receptor 2 (SST2) and the ¹⁷⁷Lu-SS0110 is used to treat the cancer.

The investigational agents are given in conjunction with their standard immunotherapy.

Study Investigator, Nuclear Medicine Physician, A/Prof Joe Cardaci had this to say about the study:



We are thrilled to offer this trial at GenesisCare, Murdoch. Our success in recruitment and the high-quality care provided to participants is a testament to the teamwork and collaboration at Murdoch and high level of engagement with Ariceum Therapeutics.

The value of being able to offer another treatment option in ES-NSCLC can't be underestimated. We look forward to seeing the important findings from this study around safety and tolerability and the level of anti-tumour activity.

Our GenesisCare Theranostics team has been expanding its research and site capabilities and establishing a strong reputation as a leading choice for conducting Theranostics trials on a global scale. The team are currently managing 8 active studies, 5 in follow up and 6 in start-up across our Western Australian and Victorian sites.

The Ariceum trial at our GenesisCare Murdoch site under the leadership of Wilna Van Der Watt and Principal Investigator A/Prof Joe Cardaci has remained the top recruiter in Australia since its site activation in June 2023.

This phase I study is testing two next generation radiotherapeutics for identification and treatment of patients with end stage non-

Haematology



works by blocking the B-cell lymphoma-2 (Bcl-2) protein and Zanubrutinib blocks the Bruton tyrosine kinase (BTK) protein.

The rationale for the combination of Sonrotoclax and Zanubrutinib is that it may work synergistically, targeting lymphoma cells in multiple ways and potentially be more effective than using one drug alone.

Study Investigator, Haematologist, Dr David Kliman had this to say about the study:



We are grateful to be able to provide this important study for patients with chronic lymphocytic leukaemia (CLL) at GenesisCare, North Shore. A priority for patients undergoing first line therapy for CLL is having a fixed-duration treatment to allow them to get back to living their lives.

This novel all-oral combination is expected to be both more efficacious and better tolerated than currently available treatments. The ongoing care provided by our trials coordinators and staff is greatly appreciated.

With 4 active studies, 4 in follow up and 2 in start-up our growing Haematology clinical trials and suite of Principal Investigators is keeping GenesisCare clinical research up-to-date within blood cancer.

Our GenesisCare, North Shore team is currently working with Principal Investigator, Haematologist Dr David Kliman on a clinical trial for untreated chronic lymphocytic leukaemia (CLL) BGB-11417-301 for study sponsor Beigene. BGB-11417-301 is a randomised phase 3 clinical trial for untreated chronic lymphocytic leukaemia sponsored by BeiGene.

The purpose is to compare the effectiveness of two combinations of anticancer drugs: Sonrotoclax (BGB-11417) and Zanubrutinib (investigational arm), and Venetoclax and Obinutuzumab (control arm). Sonrotoclax



MR-Linac program



MR-Linac teams pioneer removal of pre-treatment appointment for prostate cancer patients.

Our MR-Linac team is a world leader in delivering high dose Stereotactic Ablative Radiotherapy (SABR) for prostate cancer patients without the need for a pre-treatment planning appointment.

GenesisCare is the first to globally deliver Prostate SABR treatment via a 'sim-less' workflow with an abstract presented at the Asia Pacific Prostate Cancer Conference 2024, to showcase their research – titled 'Advanced prostate cancer treatment: MR-guided adaptive radiotherapy proves safe and effective'.³

Traditionally, a separate planning appointment is required up to two weeks before treatment. Over the last two years our teams have rigorously developed the technical processes to replace the need for a pre-treatment scan.

This shortens the patient journey from diagnosis to treatment, significantly alleviating the anxiety patients often experience when waiting for treatment. The new sim-less workflow enables our patients to focus on treatment and recovery.

The success of this project is the result of strong collaboration across various disciplines involved in the patient's radiotherapy journey. Our highly experienced Radiation Oncologists have driven the project to help improve the quality of life for their patients. Our astute Medical Physicists have carried out extensive research, testing and quality assurance.

Finally, our specialist Radiation Therapists have developed the workflows and tested delivery of new treatment methods. This work has been presented at national and international conferences, sharing our innovations with other centres across the globe highlighting the expertise that is within the GenesisCare MR-Linac team.



GenesisCare joins MOMENTUM international MR-Linac data registry

MOMENTUM is an initiative of the Elekta MR-Linac Consortium, a collaboration between industry and academia to maximise the clinical impact of the Unity MR-Linac. The MOMENTUM registry will collect clinical patient data (e.g. tumour and treatment characteristics) and technical patient data generated on the MR-Linac during treatment (e.g. treatment guidance images, duration). This data gathered across numerous centres in multiple countries represents the largest repository of MR-Linac data in the world, allowing representation of a wide cohort of patients. MOMENTUM will be the platform for GenesisCare patients to access innovative and new clinical trials on the MR-Linac. GenesisCare's participation in MOMENTUM will allow for the meaningful contribution of data that will support in the development of new treatment techniques and support improved outcomes for patients receiving radiotherapy on a MR-Linac.



Excellent outcomes for the first 100 prostate cancer patients treated on our MR-Linac's in Sydney and Perth.

The ADAPT registry has been active since 2020 where data is collected from patients who were treated at our MR-Linac sites in NSW and WA. The team have passed the 2-year milestone from where the 100th prostate cancer patient completed their radiotherapy treatment. Achieving this allows the team to review treatment outcomes for these patients. It serves as a foundation for GenesisCare to quality improve the delivery of MR-Linac radiotherapy treatments. The results of data collected show that patients treated at GenesisCare on the MR-Linac have very low rates of radiotherapy side effects and excellent treatment outcomes.³



MR-Linac Team WA (Left to right): Daniel Hughes, Amrinder Chabra, Libby Crago, Dr Hendrick Tan, Nicole Hug, Tommy Liang, Manuel Carrillo-Serrano



MR-Linac, Darlinghurst, NSW Team (Left to right): Dr Farshad Kasraei, Hillary Byrne, Vivienne Ng, Valery Peng, Satomi Higuchi, Abbey Burns, Steve Terrill, Dr Monique Heinke, Maddie Picton, Charles Tran, Dr Jeremy de Leon, Dave Crawford

Investing in the future of cancer care – Theranostics

In 2024 the GenesisCare Theranostics Research Program has grown significantly with the development of additional specialised capabilities such as radiolabelling and gamma counting services. This has enabled us to undertake increasingly complex Theranostics trials from Phase 0 imaging trials through to Phase 3 treatment trials.

In January 2024 there were four trials open to recruitment at two sites. As of December 2024, we had 9 trials open to recruitment with another 7 in start-up across three sites. In 2025 we will be increasing the number of locations we can undertake Theranostics clinical trials to 6 sites across the country.

2024 also saw the successful completion of three trials where GenesisCare had the first site activated globally, recruited the first patient globally, and met or exceeded recruitment targets. GenesisCare has now partnered with over 20 global and Australian radiopharmaceutical companies, conducting nearly 25 clinical trials. These include phase 0 through to phase 3 clinical trials some of which require complex procedures such as radio-labelling and gamma counting.

Our highly respected Nuclear Medicine Physicians, A/Prof Joe Cardaci, Dr Aviral Singh, and A/Prof Dinesh Sivaratnam are each actively involved as Private Investigators on several of the trials managed by our team, with each regularly asked to speak at international and local meetings providing presentations and insights into the work we are doing. Their lengthy experience in Australia and internationally in the field of Theranostics helps to raise recognition and ensure strong collaboration with clinicians and trial partners from across the globe.

GenesisCare works closely with several key collaborators across the country who we would not be able to conduct these trials without including SKG, Cyclowest, Quantum Pharma, Cabrini Imaging, IMED, Cabrini Health, St John of God (SJOG) and the National Imaging

Facility to ensure we can deliver high quality clinical trials. Future directions for Theranostics and clinical use of radiopharmaceuticals include taking advantage of availability of new isotopes and biological targeting strategies and the development of improved personalised dosimetry which combine radiopharmaceutical therapy with External Beam Radiation Therapy (EBRT) or systemic therapy. GenesisCare is well positioned to help lead advancements in Theranostics through its extensive experience in Theranostics clinical trials, dedicated staff, and national clinical network of integrated cancer care. The company's commitment to multidisciplinary care and its focus on research and development make it an ideal partner for advancing the future of cancer care through Theranostic and radiopharmaceutical innovations.



Expanding GenesisCare community awareness and reach

To raise awareness of the incredible work our GenesisCare research team is conducting A/Prof Joe Cardaci, Dr Aviral Singh and Research Operations Manager, Vicki Sproule each had the opportunity to be interviewed on the "Medical Forum podcast where they shared their expertise in Theranostics, precision medicine, and the management of clinical trials.



Medical Forum podcast links

Medical Forum's clinical editor, Dr Joe Kosterich interviewed [A/Prof Joe Cardaci \(ep. 4\)](#), [Dr Aviral Singh, \(ep.5\)](#) and [Vicki Sproule \(ep.6\)](#) about Theranostics and about their roles within clinical research.



WA Theranostics Team (Left to right): Dr Aviral Singh, Kate Waswo, Wilna Van Der Watt, Alexandra Burdakova, A/Prof Joe Cardaci



Cabrini Theranostics team (Left to right): Study lead: Suzi Jakicic, Centre leader: Daniel Wong, CRC: Michelle Starmans, A/Prof Dinesh Sivaratnam, Michael Pearson

Quality

The GenesisCare Research Quality team has had a productive and impactful year, making significant strides across the clinical trial and broader research program. This year, the organisation underwent Health Service Accreditation SNAP Inspection in South Australia, New South Wales, and Western Australia. The GenesisCare Clinical Trial program was assessed against the 27 action items outlined in the National Clinical Trials Governance Framework. Completing these three SNAP Inspections have provided validation for the systems and processes used to conduct clinical trials across the national network, further reinforcing the quality and consistency embedded in all our operations. These audits ensure that the clinical trial program is aligned with rigorous standards, strengthening the overall quality and safety of the trials offered to patients.

In addition to the SNAP inspections, GenesisCare Research underwent three Sponsor inspections and one Human Research Ethics Committee (HREC) inspection across our Medical Oncology and Theranostic therapeutic areas. We are pleased to share that there were no major findings, which speaks to the high standards upheld by the Principal Investigators and Research team.

A significant development this year was the growth of GenesisCare's Investigator-Initiated Clinical Trial program, supported by valuable contributions from the Consumer Engagement and Patient Experience Advisory Committee. Consumer and patient involvement play a crucial role in improving awareness of clinical trials, normalising them as a viable treatment option within the community. It also ensures that the clinical trial programs are inclusive and focused on what is most important to the patients we care for.

2024 also saw the implementation of new, network-wide systems that aim to streamline and support the clinical trial process. These systems include Site Docs, an electronic document management system, an Internal Quality Audit Framework, and a Research-specific Incident Management System. These tools help evaluate current operational processes, allowing for continuous improvement and embedding quality assurance into daily operations. Furthermore, the ongoing evaluation of processes and systems has led to the establishment of a robust bi-monthly education program. This program allows us to continuously build the knowledge and skills of our teams, further enhancing the impact of research and ensuring that GenesisCare remains at the forefront of quality clinical trial service delivery.



Partnerships

In 2024, GenesisCare continued to build on its strategic partnerships, including its longstanding support for the University of Newcastle's Radiation Therapy Honour's Program. As part of this collaboration, GenesisCare generously donated funds toward scholarships to assist students in pursuing research projects alongside their coursework and clinical placements. The organisation also provided invaluable mentorship from its expert Radiation Therapists and Radiation Oncologists to guide students through their 4th-year Radiation Therapy Honour's Research Projects.

GenesisCare remains the only private radiotherapy provider in Australia to support this important program, helping to shape the future of radiation therapy professionals.

One of the standout success stories from this initiative is Ashleigh Fasala, a newly graduated Radiation Therapist. During 2023, Ashleigh conducted her research at GenesisCare, focusing on the feasibility of reducing planning margins for patients receiving MR-Linac Radiotherapy to treat pancreatic cancer. Her work was published in the Journal of Medical Radiation Science in October 2024.



Ashleigh chose to complete her research at GenesisCare due to the organisation's strong commitment to clinical research, particularly in the MR-Linac field. She expressed gratitude for the support she received from the team, saying, "The team set me up for success and I appreciated everyone's encouragement and confidence in getting the project completed and now published."


Ashleigh, now a qualified Radiation Therapist, continues her professional journey at GenesisCare's Darlinghurst site, contributing to the high-quality care and innovation that GenesisCare is known for.



Sponsorships and events

In 2024, GenesisCare was a proud sponsor at multiple industry events where our esteemed research team had the opportunity to present key findings, learn and connect with industry peers. These events include:

- Thoracic Oncology Group Australasia (TOGA) ASM Conference – presentation facilitated by Prof Nick Pavlakis
- Medical Oncology Group of Australia (MOGA) Conference
- Asia-Pacific Prostate Cancer Conference (APCC), with the Radiation Oncology Breakfast sponsorship
- 2024 International Breast Cancer Conference – presenters included A/Prof Gillian Lamoury, A/Prof Michael Ng, Dr Yvonne Zisiadis, Nicola Forsyth and Julia Schulz. Dr Marie Burke OAM addressed the attendees at the conference dinner
- Australian and New Zealand Head and Neck Cancer Society (ANZHNCS) ASM – where Prof June Corry was a keynote speaker
- RANZCR ASM featuring a number of presentations from GenesisCare doctors
- Breast Cancer Trials ASM – presenters included A/Prof Gillian Lamoury and Dr Yvonne Zisiadis. Dr Sally Baron-Hay moderated a panel discussion
- Rare Cancers Long Lunch where we reflected on the impact we've had on people living with rare, less common, or complex cancers in Australia
- The Annual 2024 Trans Tasman Radiation Oncology Group (TROG) ASM
- Sonya McColl, Head of Research attended the National Press Club Health Journalism Awards
- The International Society of Limb Salvage (ISOLS) and the Australian and New Zealand Sarcoma Association (ANZSA) 2024 conference held in Brisbane, QLD – presentation facilitated by Prof Angela Hong. Dr David Schlect addressed the attendees at the President's Dinner.



Partnering with consumers in research and clinical trials

Ensuring all patients have information and access to clinical trials is a key focus. Together with consumers, we co-design, evaluate and review their access to and participation in clinical trials.



Consumer representatives:

People who have experienced a cancer diagnosis and /or participated in a clinical trial kindly review patient facing information to ensure it's easy to understand.



Availability of information on the GenesisCare website:

There is a new dedicated research and clinical trial page, and further page providing the active clinical trial listing, with search functionality



Co-design:

Clinical trial patient information and consent forms are routinely reviewed by consumer representatives with a "Reviewed by patients for patients" tick added to the final version.



Information available to patients in centres:

Patients can learn more via the Cancer Council brochure – "Understanding Clinical Trials" and a GenesisCare "Always Ask" postcard with links to the website is available in all centres.



Patient panels:

Held to seek advice from consumers about clinical trials including pricing, what matters most to them, how to access relevant information, and value proposition development.



Evaluate patient satisfaction with communication about clinical trials:

This is measured via a question in the patient satisfaction survey which is conducted monthly and provided to patients during their treatment.



Inclusivity initiatives:

Ensuring our care and clinical trials are culturally safe to all individuals including Aboriginal and Torres Strait Islanders (ATSI), Culturally and Linguistically Diverse (CALD) and the LGBTIQ+ community is evident through our staff education and inclusivity symbolism.

In their words

"Upon receiving a cancer diagnosis, you have to quickly become familiar with a plethora of new medical terms, especially if you're participating in a clinical trial. This can be more difficult also if English is not your first language.

As a Consumer Representative with GenesisCare, I have reviewed and contributed suggestions to many patient-facing flyers in relation to clinical trials. It's gratifying to witness their incorporation into the final versions for the benefit of patients nationwide."



Lee McKerracher

Consumer Representative with a lived experience of breast cancer.



Left to right: John Dowling, Carol Cody, Pam Belle, Doug Jones, Kerry Coles, Barbara Rohde



Left to right: Lee McKerracher (Consumer Representative), Ada Ryan (Head of Customer Experience), Maria Moran (Consumer Representative), Felicity Nevin (Multi-channel and Content Manager)

A patient's journey with clinical trials



Marty's Journey:

Embracing hope and the importance of clinical trials.

At 72, Marty's journey with prostate cancer is not just a story of positivity, but a testament to the importance of clinical trials in health care. His journey highlights the importance of being proactive with your health and how participating in clinical trials can provide new options and hope for patients.



A Life-Altering Diagnosis

Marty's health journey began in his late 50s when he was diagnosed with an enlarged prostate. For years, his PSA levels were monitored without issue—until 2019, when his PSA spiked unexpectedly. A biopsy confirmed prostate cancer, but it was caught early, allowing Marty to undergo surgery.

However, when his PSA levels rose again, Marty was introduced to a clinical trial at GenesisCare, which would offer new hope—an innovative imaging agent designed to provide more detailed information about his cancer.



The Impact of Clinical Trials

Rather than just another treatment, the trial presented an opportunity for Marty to receive new information about his cancer. "This trial gave me a chance to understand my cancer better, it gave me new information about my cancer, I could be better informed. I trusted GenesisCare and their experienced research team. Being part of something that could help others made it a no-brainer for me," says Marty. Clinical trials like this one are crucial in helping advance cancer research, and offering patients access to treatments that aren't yet available through standard care pathways. For Marty, it wasn't just about treatment—it was about contributing to the future of cancer care.



Support Every Step of the Way

Throughout the trial process, Marty was guided by a compassionate and skilled research team; his treating Dr and Principal Investigator A/Prof Joe Cardaci and his clinical research coordinators Alex and Kate who ensured he was well informed of the process and steps to be taken for Marty to participate in the trial. Marty shared, "The team were incredible. They made everything so clear and made sure I felt supported at every stage. The consent forms can be overwhelming due to the medical jargon, however, with the help of my wife, my family and the research team I was well informed before my participation."

The ongoing support from the GenesisCare Research team helped ease any concerns and gave Marty the confidence he needed to move forward with the trial, showing that clinical trials are not just about seeking medical breakthroughs but about helping provide additional treatment options for patients. The support from the research team reduced anxiety for Marty, "The Research team were efficient, and I was on the trial in record time, I wouldn't have wanted it to go any faster that is for sure."



Living Life with Confidence

Marty remains optimistic and focused on enjoying life. With a Mediterranean cruise planned and time spent with family, Marty emphasises the importance of living fully. "Cancer doesn't define me. I've learned to keep going and focus on the positives," he says.



Advice for Other Patients

Marty encourages others to be proactive when it comes to their health, "Ask about clinical trials and explore all your treatment options. Don't wait for things to happen. Clinical trials can offer alternative treatment options and give you a chance to contribute to research." Marty continued, "Review the website of your healthcare provider, they often have their clinical trials listed, review the brochures within the clinics and ask questions."



The Impact-Role of Clinical Trials

Clinical trials are vital in helping advance cancer treatment. They provide patients with access to emerging therapies and allow them to actively contribute to the development of new, more effective treatments. Marty's story is a powerful reminder that clinical trials can be a pathway to hope, progress, and a brighter future for cancer patients.



Left to right: Study Coordinator Kate, Marty, Study Coordinator Alex

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
Beyond Becquerel and Biology to Precision Radiomolecular Oncology	Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration	5/01/2024	Theranostics	Book Chapter	Nat Lenzo	
The Lancet Oncology	Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study	9/01/2024	Theranostics	Peer Reviewed Research Article	Giuseppe Cardaci, Nat Lenzo, Aviral Singh	https://doi.org/10.1016/S1470-2045(23)00638-1
Journal of Clinical Oncology	PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer—Interim safety and pharmacokinetic results.	28/01/2024	Medical Oncology	Abstract: Poster Presentation	Laurence Krieger	https://doi.org/10.1200/JCO.2024.42.4_suppl.123
Journal of Applied Medical Physics	Assessing the sensitivity and suitability of a range of detectors for SIMT PSQA	01/02/2024	Radiation Oncology	Peer Reviewed Research Article	Leon Dunn, Alessia Tamborriello, Brindha Subramanian, Xiaolei Xu, Tyrone Te Ruruku	https://doi.org/10.1002/acm2.14343
Frontiers of Oncology	Radiotherapy quality assurance in the TROG 12.01 randomised trial and its impact on loco-regional failure	04/02/2024	Radiation Oncology	Peer Reviewed Research Article	June Corry	doi: 10.3389/ fonc.2023.1333098
European Urology Oncology	Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial	5/02/2024	Radiation Oncology	Peer Reviewed Research Article	Eric Wegener, Mark Sidhom, Joseph Bucci, Jarad M. Martin	https://doi.org/10.1200/JCO.2024.42.4_suppl.123
Frontiers in Oncology	First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study	06/02/2024	Medical Oncology	Abstract: Poster Presentation	Malinda Itchins, Nick Pavlakis, Stephen J. Clarke	doi:10.3389/ fonc.2024.1305720
International Journal of Radiation Oncology Biology Physics	A Rare Cancer Arising in an Uncommon Site: Treatment of Adenoid Cystic Carcinoma of the Trachea	07/02/2024	Radiation Oncology	Abstract: Oral Presentation	June Corry	
2024 AUS MRinRT	Evaluation of population based electron-densities for oligometastatic MR-Linac patients.	10/02/2024	Radiation Oncology	Abstract: Oral Presentation	K Biggerstaff, A Chhabra, U Jelen, M Jameson, V Batumalai, M Carr	

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
2024 AUS MRinRT	Initial experience of MR-guided stereotactic body radiation therapy for cardiac targets	10/02/2024	Radiation Oncology	Abstract: Oral Presentation	H Tan, K Biggerstaff, V Batumalai, A Chhabra, T Liang, N Hug, E Leong, K Rahim, M Jameson, D Crawford, J de Leon	
2024 AUS MRinRT	Innovating prostate stereotactic treatment: A simulation-free breakthrough with MR-Linac	10/02/2024	Radiation Oncology	Abstract: Oral Presentation	D Crawford, M Carr, V Batumalai, M Picton, U Jelen, T Twentyman, M Jameson, J de Leon	
National Library of Medicine	Update on olfactory neuroblastoma	21/02/2024	Radiation Oncology	Abstract: Poster Presentation	June Corry	
Journal of Contemporary Brachytherapy	Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age	22/02/2024	Radiation Oncology	Peer Reviewed Research Article	Huong Ho, Mario Guerrieri, Michael Ng, Michael Chao	doi: https://doi.org/10.5114/jcb.2024.135630
Journal of Applied Clinical Medical Physics e14253	Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows	22/02/2024	Radiation Oncology	Peer Reviewed Research Article	Sean P. Hassan, Jeremy de Leon, Vikneswary Batumalai, Zoe Moutrie, Louise Hogan, Yuanyuan Ge, Michael G. Jameson	doi: https://doi.org/10.1002/acm2.14253
Journal of Applied Clinical Medical Physics	International collaboration between low-middle-income and high-income institutions to improve radiation therapy care delivery	22/02/2024	Radiation Oncology	Peer Reviewed Research Article	Diana Ng, Tatiana De Martin, Po Ting Wu, Peter Huang, Jennifer Davis, Jamie Nash, Sarah Knighton	doi: 10.1002/acm2.14306
Notable Current Clinical Trials in Theranostics of NEN	19th International conference on Radiopharmaceutical Therapy (ICRT) organised by World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), 2024	27/02/2024	Theranostics	Abstract: Oral Presentation	Aviral Singh	
American Association for Cancer Research	Abstract OT3-11-03: The PREDICT Registry Australia: A prospective registry to evaluate the clinical utility of a 7-gene predictive biosignature on treatment decisions in patients with ductal carcinoma in situ	29/02/2024	Radiation Oncology	Abstract: Poster Presentation	Yvonne Zissiadis, Marcus Dreosti, Sally Baron-Hay, Alexandra Feetham, Kim Kirkham, Shane Ryan	

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
The International Journal of Medical Physics Research and Practice	Technical note: Cryostat transmission characterization for MR linac – temporal stability, clinical impact and change implementation	10/03/2024	Radiation Oncology	Peer Reviewed Research Article	Urszula Jelen, Michael G. Jameson	https://doi.org/10.1002/mp.17021
Clinical Endocrinology	Initial surgical management of sporadic medullary thyroid cancer: Guidelines based optimal care – A systematic review	11/03/2024	Radiation Oncology	Peer Reviewed Research Article	June Corry	doi: 10.1111/cen.15041
International Journal of Radiation Oncology – Biology – Physics (IJROBP)	A Longitudinal Study Evaluating Sexual Health Outcomes and Prioritization in Patients Undergoing Chemoradiation for Human Papillomavirus-Associated Oropharyngeal Cancer	14/03/2024	Radiation Oncology	Peer Reviewed Research Article	June Corry	doi: 10.1016/j.ijrobp.2023.10.006
14th European Breast Cancer Conference Scientific Committee	Changes in treatment recommendations for patients with ductal carcinoma in situ using a 7-gene predictive biosignature: Analysis of the Australian predict registry	21/03/2024	Radiation Oncology	Abstract: Poster Presentation	Yvonne Zissiadis	
BMJ Open Journals	Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)	22/03/2024	Medical Oncology	Abstract: Poster Presentation	David Christie	
World Journal of Men's Health	A Systematic Review of the Association between Psychological Resilience and Improved Psychosocial Outcomes in Prostate Cancer Patients. Could Resilience Training Have a Potential Role?	31/03/2024	Radiation Oncology	Peer Reviewed Research Article	David Christie	https://doi.org/10.5534/wjmh.230319
Australian Health Review	Designing and implementing a bundle of care for patients with early-stage breast cancer: lessons from a pilot program	2/04/2024	Medical Oncology	Peer Reviewed Research Article	Yvonne Zissiadis, Nicola Forsyth, Anna Montgomery	https://doi.org/ https://doi.org/10.1071/AH24009
World Academy of Sciences Journal	Expression of microRNAs following radiation therapy and association with severity of radiotherapy-induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta-analysis	3/04/2024	Radiation Oncology	Peer Reviewed Research Article	Jagtar Singh	https://doi.org/10.3892/wasj.2024.242

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
Cells	Upregulation of the Renin–Angiotensin System Is Associated with Patient Survival and the Tumour Microenvironment in Glioblastoma	4/04/2024	Radiation Oncology	Peer Reviewed Research Article	Michael F. Fay	doi:https://doi.org/10.3390/cells13070634
The Lancet Oncology	[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial	11/04/2024	Medical Oncology	Peer Reviewed Research Article	Laurence Krieger	doi:10.1016/s1470-2045(24)00135-9
Clinical Lung Cancer	Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT)	14/04/2024	Medical Oncology	Peer Reviewed Research Article	Malinda Itchins, Nick Pavlakis	doi:10.1016/j.clcc.2024.04.008
Asia-Pacific Journal of Clinical Oncology	A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia	18/04/2024	Radiation Oncology	Peer Reviewed Research Article	Laurence Krieger	doi:10.1111/ajco.14054
ANZSNM ASM Conference 2024	⁶⁴ Cu-SARTATE as a PET imaging probe for canine osteosarcoma	25/04/2024	Theranostics	Abstract: Poster Presentation	Nat Lenzo	
ANZSNM ASM Conference 2024	Case studies in Ac-225 DOTATATE and Tb-161 DOTATATE in neuroendocrine tumours (NETS)	25/04/2024	Theranostics	Abstract: Oral Presentation	Nat Lenzo	
ANZSNM ASM conference 2024	Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration resistant prostate cancer (ProstACT-SELECT preliminary results)	25/04/2024	Theranostics	Abstract: Oral Presentation	Nat Lenzo	
American Association for Cancer Research	Abstract PO4-22-05: Changes in Treatment Recommendation for Patients with Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Australia Study	1/05/2024	Radiation Oncology	Abstract: Poster Presentation	Yvonne Zissiadis, Marcus Dreosti; Sally Baron-Hay	https://doi.org/10.1158/1538-7445.SABCS23-PO4-22-05

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
ASMIRT conference 2024	Advancing prostate stereotactic treatment with MR-Linac: Simulation-free innovations	8/05/2024	Radiation Oncology	Abstract: Oral Presentation	Vikneswary Batumalai	
The Lancet Oncology	Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial	9/05/2024	Medical Oncology	Abstract: Oral Presentation	Laurence Krieger	https://doi.org/10.1200/JCO.2023.41.6_suppl.LBA442
ESTRO 2024 – Pages 2364–2365	Revolutionising prostate stereotactic treatment with a novel simulation-free approach using MR-Linac	9/05/2024	Radiation Oncology	Abstract: Poster Presentation	Jeremy De Leon, Dr Hendrick Tan	
ESTRO 2024 pages 2919- 2921	Analysis of group consensus peer review process in MR-Linac patients: outcomes and feasibility	9/05/2024	Radiation Oncology	Abstract: Poster Presentation	Jeremy De Leon, Dr Hendrick Tan	
ESTRO 2024 – Pages 1924–1926	Initial Experience of MR-Guided Stereotactic Body Radiation Therapy for Cardiac Targets	9/05/2024	Radiation Oncology	Abstract: Poster Presentation	Jeremy De Leon, Dr Hendrick Tan	
Journal of Clinical Medicine	Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours	20/05/2024	Radiation Oncology	Peer Reviewed Research Article	June Corry	doi: 10.3390/jcm13113020
Meeting Abstract: 2024 ASCO Annual Meeting	Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.	28/05/2024	Medical Oncology	Abstract: Poster Presentation	Nick Pavlakis	
Radiotherapy & Oncology	2176: Implementation of a distributed PSQA model across a network of matched linear accelerators for SABR	29/05/2024	Radiation Oncology	Abstract: Poster Presentation	Leon Dunn, Simon Goodall, Michael Jameson	doi:10.1016/S0167-8140(24)02426-5
International Journal of Radiology & Radiation Therapy	Keratinocyte cancer of the lower limb in the frail elderly – acceptable results for 96 lesions treated with a shortened radiotherapy protocol	30/05/2024	Radiation Oncology	Peer Reviewed Research Article	Bradley Wong	doi: 10.15406/ijrrt.2024.11.00387

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
Journal of Nuclear Medicine Technology	First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer	13/06/2024	Theranostics	Peer Reviewed Research Article	Nadia Falzone, Dinesh Sivaratnam	htdoi: 10.2967/ jnmt.123.267067
ASTRO	Radiotherapy for Skin field cancerisation	14/06/2024	Radiation Oncology	Invited Speaker Presentation/ Live Cases	Andrew Potter	
Webinar Slide Deck	Modern Radiation Therapy Techniques for the Treatment of Keratinocyte Carcinomas (Non-Melanoma Skin Cancers)	14/06/2024	Radiation Oncology	Invited Speaker Presentation/ Live Cases	Andrew Potter	
The Journal of Medical Radiation Services	Evaluation of the clinical outcomes and patient satisfaction related to the use of internal eye shields for electron external beam radiation therapy	14/07/2024	Radiation Oncology	Peer Reviewed Research Article	Bryan Burmeister	doi: 10.1002/ jmrs.812
Clinical and Translational Radiation Oncology	Does a peer review group consensus process for MR-Linac patients affect clinical care? Evaluation of impact and feasibility	17/07/2024	Radiation Oncology	Peer Reviewed Research Article	Vikneswary Batumalai, Jeremy de Leon, Eugene Leong, Kasri Rahim, Farshad Kasraei, Charles Tran, Tommy Liang, Katrina Biggerstaff, Michael G. Jameson, Nicole Hug, Hendrick Tan	doi.org/10.1016/j. ctro.2024.100816
Journal of Nuclear Medicine	Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study	17/07/2024	Radiation Oncology	Peer Reviewed Research Article	Siddhartha Baxi	doi:10.2967/j numed.124.267988
Oral Oncology	Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer – A narrative review	29/07/2024	Radiation Oncology	Peer Reviewed Research Article	June Corry	doi: 10.1016/j. oraloncology. 2024.106975
TROG	Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03	10/08/2024	Medical Oncology	Abstract: Poster Presentation	Peter O'Brien, David Christie	

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
European Society for Radiotherapy and Oncology	Adapting outside the box: Simulation-free MR-guided stereotactic ablative radiotherapy for prostate cancer	28/08/2024	Radiation Oncology	Peer Reviewed Research Article	Jeremy de Leon, Urszula Jelen, Madeline Carr, David Crawford, Maddison Picton, Charles Tran, Laura McKenzie, Valery Peng, Tania Twentyman, Michael G. Jameson, Vikneswary Batumalai	https://doi.org/10.1016/j.radonc.2024.110527
RANZCR	Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer – an Australian, retrospective, multi-institutional study.	12/09/2024	Radiation Oncology	Abstract: Oral Presentation	Michael Ng	
Artera RANZCR	Artificial intelligence steering testosterone deprivation treatments in prostate cancer external-beam radiotherapy (ASTuTE) trial	12/09/2024	Radiation Oncology	Abstract: Poster Presentation	Michael Ng	
Clinical and Translational Radiation Oncology	The impact of rectal spacers in MR-guided adaptive radiotherapy	25/09/2024	Radiation Oncology	Peer Reviewed Research Article	Vikneswary Batumalai, David Crawford, Maddison Picton, Charles Tran, Urszula Jelen, Madeline Carr, Michael Jameson, Jeremy de Leon	https://doi.org/10.1016/j.ctro.2024.100872
International Journal of Radiation Oncology Biology Physics	Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care	28/09/2024	Radiation Oncology	Peer Reviewed Research Article	Michael Back, George Hruby, Dasantha Jayamanne, Andrew Kneebone, Gillian Lamoury, Thomas Eade	doi: 10.1016/j.ijrobp.2024.09.041
Journal of Applied Clinical Medical Physics	Dosimetric impact of variable air cavity within PTV for rectum cancer	2/10/2024	Radiation Oncology	Peer Reviewed Research Article	Eujin Chan, Simon K. Goodall, Paul Moorfoot, Michael Jameson, Leon Dunn	https://doi.org/10.1002/acm2.14539
Journal of Medical Radiation Sciences	Intrafraction motion and impact of margin reduction for MR-Linac online adaptive radiotherapy for pancreatic cancer treatments	12/10/2024	Radiation Oncology	Peer Reviewed Research Article	Ashleigh Fasala, Madeline Carr, Jeremy de Leon, Abbey Burns, Vikneswary Batumalai	doi:https://doi.org/10.1007/s00259-020-05143-9
Clinical Oncology	Cost-Outcome of Radiotherapy for Local Control and Overall Survival Benefits in Breast Cancer	14/10/2024	Radiation Oncology	Peer Reviewed Research Article	Vikneswary Batumalai	https://doi.org/10.1016/j.clon.2024.07.007

Publications for 2024

Name of journal/ conference	Title	Published date	Subspecialty	Publication type	GenesisCare authors	DOI
Journal of Medical Imaging and Radiation Oncology	Nature and impact of symptoms at time of initial presentation for patients with glioblastoma	22/10/2024	Radiation Oncology	Peer Reviewed Research Article	D Jayamanne, M Back	doi: 10.1111/1754-9485.13796
International Journal of Radiation Oncology Biology Physics	A Hard Truth to Swallow: Critically Evaluating the MD Anderson Dysphagia Inventory (MDADI) as an Endpoint in Human Papillomavirus-associated Oropharyngeal Cancer Trials	31/10/2024	Radiation Oncology	Peer Reviewed Research Article	June Corry	doi: 10.1016/j.ijrobp.2024.05.005
COSA	Bundling and patient navigation in early-stage breast cancer care Interim findings of a 100 patient pilot study	15/11/2024	Radiation Oncology	Abstract: Poster Presentation	Yvonne Zissiadis, Nicola Forsyth, Julia Schulz	
Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference 2024	Investigating the Exclusion of MLC and Jaw Characterization from Monaco TPS in Complex Stereotactic Radiotherapy	20/11/2024	Radiation Oncology	Abstract: Poster Presentation	L Munoz, P. McLoone	

References: **1.** Australian Institute of Health and Welfare (AIHW) 2024, Cancer data in Australia, updated 18 November 2024, <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia> **2.** Sacher, A.G., Villalona-Calero, M., O'Neil, B.H., Rodon, J., Doi, T., Postel-Vinay, S., Ghiringhelli, F., Yamamoto, N., Wahlroos, S., Villaruz, L., El-Helali, A., Fujiwara, Y., Addeo, A., Lin, C., Fontana, E., Chuang, C., Liu, C., Eggert, T., Penel, N. and Prenen, H. (16AD). Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors. ESMO Congress 2024. **3.** Picton, M., Batumalai, V., Tran, C., Crawford, D., Kasraei, F., Jelen, U., Jameson, M., Twentyman, T., Peng, V., Leong, E., Tan, H., Rahim, K., Lim, T. and de Leon, J. Advanced prostate cancer treatment: MR-guided adaptive radiotherapy proves safe and effective. In: Asia-Pacific Prostate Cancer Conference 2024.